Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Varespladib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A known ✓ | P14555 | 19/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 7/20 | 1.00 |
| ▸ | PLA2G10 | O15496 | 6/20 | 1.00 |
| ▸ | PLA2G2E | Q9NZK7 | 6/20 | 1.00 |
| ▸ | PLA2G5 | P39877 | 5/20 | 1.00 |
| ▸ | PLA2G2F | Q9BZM2 | 4/20 | 1.00 |
| ▸ | PLA2G2D | Q9UNK4 | 4/20 | 1.00 |
| ▸ | PLA2G6 | O60733 | 1/20 | 1.00 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 1.00 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 1.00 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 1.00 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Varespladib SCHEMBL29358982 | 1.00 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL7682372 | 0.93 | PLA2G2A (0.87) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL818585 | 0.92 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL5150404 | 0.92 | PLA2G2A (0.84) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| Varespladib SCHEMBL1232548 | 0.91 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| Varespladib SCHEMBL29430154 | 0.91 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| Varespladib Methyl SCHEMBL29378302 | 0.91 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| Varespladib Methyl SCHEMBL25678 | 0.91 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL6812616 | 0.90 | PLA2G2A (0.82) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL5710700 | 0.90 | PLA2G2A (0.82) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048880-B2 | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies | ANTHERA PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | claimed |
| US-20110207710-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | claimed |
| EP-2341045-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor | Eli Lilly and Company (US) | 2011-07-06 | — | — | EP | claimed |
| EP-2154958-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | Anthera Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | claimed |
| US-20090131396-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | claimed |
| US-20090062369-A1 | USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS | ANTHERA PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | claimed |
| WO-2008137803-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| EP-1157704-B1 | SPLA2 INHIBITORS FOR THE TREATMENT OF ISCHAEMIC REPERFUSION INJURY | SHIONOGI & CO (JP) | 2006-06-14 | — | — | EP | claimed |
| EP-1058547-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING THE PHOSPHOLIPASE INHIBITOR SODIUM 3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-PHENYLMETHYL)-1H-INDOL-4-YL]OXY]ACETATE | SHIONOGI & CO (JP) | 2005-11-23 | — | — | EP | claimed |
| EP-1073440-B1 | sPLA 2 INHIBITOR ESTERS | LILLY CO ELI (US) | 2004-10-20 | — | — | EP | claimed |
| EP-0887342-A2 | Process for preparing 4-substituted-1H-indole-3-glyoxamides | ELI LILLY AND COMPANY (US) | 1998-12-30 | — | — | EP | claimed |
| WO-1998047508-A1 | METHOD FOR THE TREATMENT OF STROKE USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1998-10-29 | — | — | WO | claimed |
| US-5733923-A | SECRETORY PANCREATIC PHOSPHOLIPASE A2 | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | claimed |
| US-5654326-A | SEPTIC SHOCK; HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | claimed |
| EP-0533840-B1 | TREATMENT OF CHRONIC RENAL FAILURE WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS | DU PONT (US) | 1996-12-11 | — | — | EP | claimed |
| WO-1995026724-A1 | IMPROVEMENT OF INSULIN SENSITIVITY WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES | EIDE IVAR KONRAD (NO) | 1995-10-12 | — | — | WO | claimed |
| EP-0675110-A1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-04 | — | — | EP | claimed |
| EP-0253310-B1 | Angiotensin II receptor blocking imidazoles | DU PONT (US) | 1994-10-26 | — | — | EP | claimed |
| US-5210079-A | Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-11 | — | — | US | claimed |
| US-5155118-A | Administering angiotensin inhibitor | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207710-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | PLA2G12A, PLA2G3, PCSK9 | PLA2G2A 23/4885PLA2G1B 16/4885PLA2G10 10/4885 |
| US-20090062369-A1 | USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS | PLA2G12A, PLA2G3, PLA2G2E | PLA2G2A 15/4885PLA2G1B 5/4885PLA2G10 10/4885 |
| US-20090131396-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | PLA2G12A, PLA2G3, PCSK9 | PLA2G2A 23/4885PLA2G1B 16/4885PLA2G10 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.